Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald D Alvarez

Showing results (91-100 of 211) with videos related to

Pageof 22
Sort By:
Gynecologic Oncology|January 22, 2005
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene deliveryMinghui Wang, Akseli Hemminki, Gene P Siegal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Transcriptional blocks limit adenoviral replication in primary ovarian tumorMeredith A Preuss, John T Lam, Minghui Wang, et al.
Gynecologic Oncology|December 17, 2003
Complications of indwelling venous access devices in patients with gynecologic malignanciesJacob M Estes, Rodney Rocconi, J Michael Straughn, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2013
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effectsSung Yong Lee, Tae Heung Kang, Jayne Knoff, et al.
Gynecologic Oncology|July 4, 2025
What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practicesMargaret I Liang, Emeline M Aviki, Rinki Agarwal, et al.
Gynecologic Oncology|December 7, 2007
Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell linesT Michael Numnum, Sharmila Makhija, Baogen Lu, et al.
Gynecologic Oncology|April 9, 2014
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group studyRonald D Alvarez, Michael W Sill, Susan A Davidson, et al.
Molecular Cancer Therapeutics|May 4, 2012
Smoothened antagonists reverse taxane resistance in ovarian cancerAdam D Steg, Ashwini A Katre, Kerri S Bevis, et al.
Gynecologic Oncology|November 26, 2015
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group studyRodney P Rocconi, Heather A Lankes, William E Brady, et al.
Gynecologic Oncology|July 12, 2011
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignanciesAkila Subramaniam, Kenneth H Kim, Shannon A Bryant, et al.
Pageof 22

Showing results (91-100 of 211) with videos related to

Sort By:
Pageof 22
Gynecologic Oncology|January 22, 2005
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene deliveryMinghui Wang, Akseli Hemminki, Gene P Siegal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Transcriptional blocks limit adenoviral replication in primary ovarian tumorMeredith A Preuss, John T Lam, Minghui Wang, et al.
Gynecologic Oncology|December 17, 2003
Complications of indwelling venous access devices in patients with gynecologic malignanciesJacob M Estes, Rodney Rocconi, J Michael Straughn, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2013
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effectsSung Yong Lee, Tae Heung Kang, Jayne Knoff, et al.
Gynecologic Oncology|July 4, 2025
What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practicesMargaret I Liang, Emeline M Aviki, Rinki Agarwal, et al.
Gynecologic Oncology|December 7, 2007
Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell linesT Michael Numnum, Sharmila Makhija, Baogen Lu, et al.
Gynecologic Oncology|April 9, 2014
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group studyRonald D Alvarez, Michael W Sill, Susan A Davidson, et al.
Molecular Cancer Therapeutics|May 4, 2012
Smoothened antagonists reverse taxane resistance in ovarian cancerAdam D Steg, Ashwini A Katre, Kerri S Bevis, et al.
Gynecologic Oncology|November 26, 2015
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group studyRodney P Rocconi, Heather A Lankes, William E Brady, et al.
Gynecologic Oncology|July 12, 2011
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignanciesAkila Subramaniam, Kenneth H Kim, Shannon A Bryant, et al.
Pageof 22